Psych Congress NetworkPsychedelic Therapies at a Turning Point: How Recent Federal Actions May Reshape Psychiatric Care

⚖️ Legal / Ethical Complexity

Psych Congress Steering Committee members Andrew Penn and Charles Raison commented on federal developments shaping psychedelic drug review: FDA priority review vouchers issued to Compass Pathways, Usona Institute, and Transcend Therapeutics, plus a Trump executive order intended to streamline interagency coordination.

What’s at Stake

• The voucher program moves three sponsors up the FDA review queue but does not modify approval standards or guarantee approval.
• Experts contrast current sponsors with the 2024 Lykos/MDMA rejection, noting trial designs more aligned with FDA expectations from inception.
• Psilocybin-based therapies for treatment-resistant depression and MDD are nearing Phase 3 completion and represent the most likely near-term approval candidates.
• The executive order may compress coordination delays historically tied to Schedule I research constraints, though Schedule I status itself remains unchanged.

What to Watch

• Track Phase 3 readouts from Compass, Usona, and Transcend Therapeutics over the next year.
• Anticipate the first regulatory decisions within roughly 12 months per expert commentary.
• Follow DEA scheduling discussions that would need to follow any approval.
• Note practice infrastructure questions around session monitoring, REMS, and reimbursement before approvals arrive.